Three-dimensional structure of human serum albumin by Twigg, Pamela D. et al.
NO1- 4057 :
THREE-DIMENSIONAL STRUCTURE OF HUMAN SERUM ALBUMIN
Daniel C. Carter, Xiao-mln He, Pamela D. Twigg
and Elena Casale
The Space Science Laboratory
ES76 Biophysics
Marshall Space Flight Center, AL 35812
All correspondence should be to Daniel C. Carter at the above address. Phone is (205) 544-5492. Fax is
(205) 544-1777.
ABSTRACT
The binding locations to human serum albumin (HSA) of several drug molecules have been determined at
low resolution using crystallographic methods. The principal binding sites are located within subdomains IIA
and IIIA. Preliminary studies suggest that an approach to increasing the in vivo efficacy of drugs which are
rendered less effective or ineffective by virtue of their interaction with HSA, would be the use of competitive
displacement in drug therapies and/or the development of a general inhibitor to the site within subdomain
IIIA. These findings also suggest that the facilitated transfer of various ligands across organ/circulatory
interfaces'such as the liver, kidney, and brain may be associated with binding to the IIIA subdomain.
Although serum albumin plays several important roles as the major protein of the circulatory system, it
has been suggested that the molecule's high affinity for low molecular weight ligands may be its principal
function (1). Over the past several decades there have been voluminous works describing the binding affinities
and predicted locations of various endogenous and exogenous ligands to HSA. The reader is referred to the
informative reviews by Kragh-Hannsen (2), Fehske et. al. (3), and Peters (4) and references cited therein.
Previously, we described the structure of HSA as being comprised of three domains each of which were found
to be the product of two helical subdomains consistent with the current understanding of the molecule's
primary structure (5,6). These six subdomains have since been referred to as IA, IB, HA, IIB, etc. We also
reported that the binding of a chemically diverse group of compounds occurs primarily within two of these
helical subdomains. These findings are in further agreement with several studies which indicate the presence
of two to three high affinity binding sites within the molecule (2). More extensive experiments have recently
been conducted by our group in an effort to identify the classical binding sites described by Sudlow and others
(4,7). Sudlow grouped drug binding to HSA into three distinct categories, which he denoted as Site I for
warfarin, Site II for the diazapines, and Site III for digitoxin. Although there is no complete agreement within
the literature regarding these sites, warfarin is believed to bind primarily in domain II (3,4,8), the diazapines in
domain III (9), and digitoxin, in an independent but unknown location (3,4). other studies indicate, however,
that digitoxin competes with salicylates and warfarin for a common binding site (2,10). In this paper we
present our preliminary findings regarding the major binding locations on HSA for several pharmaceutical
compounds.
At the current resolution of 4.0 A the primary binding pockets within IIA and IIIA _e cavities of
approximately 8 A X 12 A X 18 A which are exposed to the solvent channels through an opening of -9-10 A in
diameter. Large, well-ordered side chains protrude into these binding pockets where they appear to play a
major role in ligand binding through stacking interactions. The identity of these amino acid residues should
become evident once the model is fit to the electron density at higher resolution.
The general binding locations of several exogenous and endogenous ligands have been determined at
various low resolutions using standard crystallographic methods, table 1. An illustration of various binding
locations on HSA for several ligands is shown pictorially in figure 1. There exists, based on the current binding
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studies,atleastfourdistinctmajorbindingregionsonHSA. Location1,subdomainIIIA, whichis themost
activeand accommodatingonHSAwithfewexceptions,e.g.warfarin,displayshighaffinitiesfor mostorganic
compounds.Location2,subdomainIIA, hassimilarbindingpropertiesto IIIA but in thesepreliminary
studieshowsanabsenceof long-chainfattyacidbinding.Basedontheaminoacidsimplicated,IIA maybe
inferredtobethebilh'ubinhighaffinitysite. Location3,theIA-IB interfaceisanadditionalbindingsitefor
aspirin(althoughweak),decanol,andpossiblytheshortchainfattyacids.Location4,subdomainI13,
possessesahighaffinitysurface,thusfar uniquetolongchainfattyacidsandtryptophan.Thegeneralbinding
locationsof thecompoundsofSudlow'sgroup,warfarin(SiteI), diazapam(SiteII), anddigitoxin(SiteIII),
weredeterminedcrystallographically.Thecrystallographicstudiesareingeneralagreementwiththeexpected
locationsindicatingmajorbindingsitesfor warfarinwithinIIA, andfor diazapamin IIIA. Digitoxin,also
showsamajorbindingsitewithinsubdomainIIIA andasecondarysiteattheinterfacebetweenIA andIIA.
SudlowsSiteIII then,differsfromSiteII onlyin thenatureof thesecondarybindingsites.
It is interestingto note that the amino acid sequences most highly conserved between bovine, human, and
rat albumins; Cys-34, Trp-212, sequence 143 through 155 and sequence 244 through 263 (11), all appear to be
in regions involved in ligand binding. For example, residues 143 through 155, an aromatic sequence,
corresponds with the region of Location 4, the second major long-chain fatty acid binding site. Certainly the
correlation of the conserved amino acids sequences with occurrence of binding sites within HSA supports the
idea that the principal role of this molecule in the circulatory system is to aid in the transport, distribution,
and metabolism of both essential and foreign small molecules. Given the unique structure of serum albumin
and the following interesting observations: (i) there is an asymmetric charge distribution within the primary
structure of HSA at pH 7, of -9, -8, and -2 for domains I, II, and III respectively, thus indicating a potential
amphoteric nature, (ii) HSA has been shown to interact with the cell membrane thereby aiding in the delivery
of certain molecules, e.g. thyroxine, to the cell (12), (iii) subdomain IIIA appears to be the primary binding
site for a variety of molecules, (iv) serum albumin is implicated in the facilitated transfer of ligands across
various organ/circulatory interfaces, such as the liver, intestine, kidney, and brain; it is tempting to speculate
whether the serum albumins possess membrane spanning properties. If this were the case, one might expect
that HSA would unfold at the hinge region between IIA and IIB allowing the more lipophylic tail (subdomains
liB, IIIA, and IIIB) of HSA to span the membrane while the more polar head of the molecule (subdomains
IA, IB, IIA) would remain on the surface of the membrane, thus releasing the bound ligands in subdomain
IliA into the cell. Perhaps then, ligand binding within subdomain IIIA is'a prerequisite for the facilitated
transfer of many endogenous and exogenous compounds at organ/circulatory interfaces.
As we continue to characterize the nature of bound ligands to serum albumin and correlate this
information with a wealth of drug and ligand binding data in the literature; it will become possible to predict
important displacement interactions for a variety of endogenous and exogenous ligands. Accordingly, this
suggests that an approach to increasing the in vivo efficacy of drugs which are rendered less effective or
ineffective by virtue of their interaction with HSA would be the use of competitive displacement in drug
therapies and/or the development of a general inhibitor to the site within subdomain IIIA.
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TABLE I LIG_h_D BINDING LOCATIONS TO HSA
Data Set Ligand D N Rf Obsv. Loc. Pred. Loc.
HTRPIA Tryptophan
HPALIA Palmitate
HMYRIA Myristate
HMRGLIA Glucose
HSAAIA Aspirin
HMRWNIA Warfarin
HSAVlA Diazapam
HDGXlA Digitoxin
5.0 3198 0.093 IIIA, IB, IIA^IB
5.9 2432 0.066 IIIA, IB
6.0 1923 0.095 IlIA
5.8 3106 0.10 IIIA
4.0 7362 0.ii IIIA, IIA
5.0 2555 0.167 IIA
6.8 2075 0.118 IIIA
5.0 3751 0.137 IIIA, IA^IIA
HCHLOIA Chlofibrate 6.0 2175 0.138 IIIA
HMRIBIA Ibuprofen 6.0 2402 0.215 IIIA
HAZTIA AZT 4.0 7548 0.124 IIIA
It should be noted that these data represent preliminary research into
ligand binding of HSA. The binding results can also be affected by the
composition of the solvent, the pH, and protein packing within the crys-
tal. Where D = minimum d-spacing for data collected, N = number of
unique reflections measured, Rf = agreement between native and ligand
for Fobs.s
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